Tolinapant (ASTX660) is an orally active small molecule antagonist of cIAP1/2 and XIAP. It promotes immunogenic cell death (ICD) in sensitive head and neck squamous cell carcinoma (HNSCC) models in vitro, supporting its investigation in cancer immunotherapy and apoptosis research.